Investigating the expression levels of BRCA1, BRCA2, CHEK2, BRIP1, RAD51, and BARD1 between triple-negative breast cancer (TNBC) and non-TNBC subtypes. Here, CHEK2 is linked to triple-negative breast carcinoma.